We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

USB:NYSEU.S. Bancorp Analysis

Data as of 2026-06-01 - not real-time

$54.85

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

U.S. Bancorp is trading comfortably above its 20‑day and 50‑day moving averages, with the MACD histogram turning positive and the MACD signal flagged as bullish, indicating short‑term momentum in its favor. Fundamentally, the stock’s trailing P/E of around 11.5 sits well below the industry average of 16.6, while the forward P/E contracts to under 10, suggesting a valuation gap that analysts are pricing in with a mean target near $63 and a median target of $63, implying roughly a 15% upside. The dividend yield of 3.76% coupled with a payout ratio under 45% reinforces cash flow strength and supports the dividend’s sustainability.
Recent analyst commentary from Truist Securities and Goldman Sachs highlights USB as a top regional bank pick, emphasizing its solid earnings margins, robust ROE and a strong balance sheet with ample cash relative to debt. The combination of a bullish technical set‑up, a value‑oriented valuation, and a high‑yield, sustainable dividend makes the stock attractive across multiple horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price above short‑term moving averages and bullish MACD
  • Attractive dividend yield with sustainable payout
  • Analyst buy consensus and near‑term upside potential

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Valuation gap relative to peers (low P/E, forward P/E under 10)
  • Consistent earnings growth and strong operating margins
  • Continued dividend income reinforcing total return

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Durable regional banking franchise with solid ROE
  • Sustainable cash flow supporting dividend and balance‑sheet strength
  • Undervalued relative to industry metrics offering long‑term upside

Key Metrics & Analysis

Financial Health

Revenue Growth4.60%
Profit Margin29.29%
P/E Ratio11.5
ROE12.35%
ROA1.14%
P/B Ratio1.5
Op. Cash Flow$9.6B
Industry P/E16.6

Technical Analysis

TrendBullish
RSI51.2
Support$52.33
Resistance$57.05
MA 20$54.61
MA 50$54.50
MA 200$52.05
MACDBullish
VolumeDecreasing
Fear & Greed Index94.07

Valuation

Fair Value$50.83
Target Price$63.55
Upside/Downside15.87%
GradeUndervalued
TypeValue
Dividend Yield3.76%

Risk Assessment

Beta0.93
Volatility19.48%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.